StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Investment analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 5.6 %

NYSE BTX opened at $1.78 on Monday. The business’s 50 day moving average is $1.98 and its two-hundred day moving average is $1.99. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The stock has a market capitalization of $104.71 million, a price-to-earnings ratio of -0.78 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.